For the year ending 2025-12-31, STRO had -$132,174K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 102,484 |
| Operating expenses | 260,851 |
| Loss from operations | -158,367 |
| Loss before provision for income taxes | -191,179 |
| Income tax expense | -93 |
| Net loss | -191,086 |
| Depreciation and amortization | 7,324 |
| Accretion of discount on marketable securities | 3,435 |
| Stock-based compensation | 14,008 |
| Non-cash lease expenses | 5,884 |
| Impairment charges | 1,694 |
| Realized gain on sale of equity securities | 0 |
| Unrealized gain on equity securities | 0 |
| Non-cash interest expense on deferred royalty obligation | 38,208 |
| Other | -571 |
| Accounts receivable | -4,639 |
| Prepaid expenses and other assets | -19,350 |
| Accounts payable | -2,468 |
| Accrued compensation | 1,737 |
| Accrued expenses and other liabilities | 3,552 |
| Deferred revenue | -69,729 |
| Change in operating lease liability | -7,480 |
| Net cash used in operating activities | -177,231 |
| Purchases of marketable securities | 264,950 |
| Maturities of marketable securities | 253,766 |
| Sales of marketable securities | 57,892 |
| Proceeds from sale of equity securities, net | 0 |
| Purchases of equipment and leasehold improvements | 1,695 |
| Net cash provided by (used in) investing activities | 45,013 |
| Proceeds from sales of common stock, net of issuance costs | 0 |
| Proceeds from sales of common stock to ipsen biopharmaceuticals, inc. (usa) | 0 |
| Payments of debt | 0 |
| Proceeds from exercise of common stock options | 4 |
| Taxes paid related to net share settlement of restricted stock units | 332 |
| Proceeds from employee stock purchase plan | 372 |
| Net cash provided by financing activities | 44 |
| Net increase in cash, cash equivalents and restricted cash | -132,174 |
| Cash, cash equivalents and restricted cash at beginning of year | 191,162 |
| Cash, cash equivalents and restricted cash at end of year | 58,988 |
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)